Navigation Links
Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage
Date:3/2/2012

MUMBAI, India, March 2, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK)

The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates.  While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material.  These forecasts are subject to risks identified under "Safe Harbor Statement" below.

Groupe Athena, Inc. (Pink sheets GATA.PK) has previously announced they have approximately $60 million in customer orders that they are processing and they expect to be able to convert at least two thirds or approximately $40 million into revenue for the current fiscal year. The company is extremely pleased to issue this guidance update and announce that due to several factors including additional order flow and the recent equipment acquisitions, revenue should increase at least 10% or a minimum of $4 million. Earnings are also expected to increase similarly.  

The company also announced they are in talks with several regional drug manufacturers as part of an effort to help alleviate the recently announced severe, potentially life threatening shortage of vital cancer drugs in the United States including methatrexate, one of the most widely used. The company expects developments in the near term and has committed to make every effort to "fast track" any trials or regulatory filings necessary.

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Profits Soar on Record Revenues
2. Groupe Athena, Inc. Provides Guidance on Current Orders
3. Groupe Athena, Inc. Clarifies Previous Guidance
4. Groupe Athena, Inc. Reports Record First Quarter Revenues
5. Publicis Healthcare Communications Group Redefines Publicis Groupes Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health
6. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
9. Aethlon Medical Clarifies News Report
10. Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Ischemic Stroke Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Ischemic Stroke Market and Competitive Landscape Highlights ... Stroke pipeline products, Acute Ischemic Stroke epidemiology, ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National ... encouraging people all over the United States to thank a nurse who's made a ... will donate $5 to the American Red Cross of San Diego/Imperial Counties (up to ...
(Date:5/5/2016)... Boston, MA (PRWEB) , ... May 05, 2016 , ... ... stress becomes a constant presence, it can weaken the immune system and increase inflammation, ... Ami B. Bhatt, director of the adult congenital heart disease program at Harvard-affiliated Massachusetts ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group ... today announced a new collaboration with Imerman Angels to expand outreach and ... the world. , “Imerman Angels provides an emotional lifeline to patients and families facing ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 ... and up 27 percent since 2012. , The results of the 2015 ASDS Survey ... increase in skin cancer treatments and the growing popularity of soft-tissue fillers and body ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Liposuction specialist Marcia ... Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s ... chosen to address the conference about her unique specialization in treating Lipedema. Dr. Byrd ...
Breaking Medicine News(10 mins):